Bio-Rad Laboratories, Inc. (BIO-B) is a Medical devices company in the Healthcare sector, listed on New York Stock Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for Bio-Rad Laboratories, Inc. in 2026. The next earnings report is expected on October 22, 2026.
Next earnings date
22 Oct 2026
In 63 days
EPS estimate
2.38
Revenue estimate
651.1M
Past earnings
Latest earnings analysis
Bio-Rad Laboratories beat consensus estimates in its latest earnings report, with EPS of $2.62 coming in 49.9% above expectations and revenue of $651 million exceeding estimates by 4.3%. In the previous report, EPS missed estimates while revenue came in ahead of expectations.
No dividend history available.
Bio-Rad Laboratories, Inc. creates, manufactures, and markets products essential for life science research and clinical diagnostics. Its operations span globally, covering territories such as the United States, Europe, Asia, Canada, and Latin America. The company's business is organized into two main divisions: Life Science and Clinical Diagnostics. The Life Science division develops and provides a comprehensive array of reagents, laboratory apparatus, and instruments. These are vital for various applications, including scientific research methodologies, biopharmaceutical production processes, and food quality testing. This segment dedicates its efforts to key areas within the life sciences, such as proteomics, genomics, biopharmaceutical development, cellular biology, and ensuring food safety. Its diverse clientele includes academic institutions (universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology researchers, and both food producers and testing laboratories. Conversely, the Clinical Diagnostics division specializes in designing, producing, selling, and supporting diagnostic test systems, informatics solutions, test kits, and specific quality control measures for clinical laboratories. This segment furnishes reagents, instrumentation, and software precisely tailored to address particular requirements within the in vitro diagnostics market. Its products are utilized by reference laboratories, hospital labs, state-operated newborn screening facilities, physicians' private offices, and blood transfusion centers. Furthermore, Bio-Rad offers systems and products designed for separating intricate chemical and biological substances, as well as for identifying, analyzing, and purifying their individual components. The company distributes its offerings through a multi-channel approach, leveraging both its direct sales force and a network of distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was established in 1952 and its corporate headquarters are located in Hercules, California.
Bio-Rad Laboratories, Inc. (BIO-B) is scheduled to report earnings on October 22, 2026.
Bio-Rad Laboratories, Inc. (BIO-B) last reported earnings on August 4, 2026.
Bio-Rad Laboratories, Inc. (BIO-B) is listed on New York Stock Exchange.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.